APO RESEARCH · REPORT
Cabazitaxel
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Product & engineering
Understand the product.
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Selected research
Market Structure
Global Cabazitaxel Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
USA is the largest Cabazitaxel market with about 95% market share. Europe is follower, accounting for about 3% market share.The key manufacturers are Sanofi, Tapi Teva, Fuan Pharmaceutical Group, Fujian Yewpark Biological etc. Top 3 companies occupied about 99% market share.
This report provides an overview of the global Cabazitaxel market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Cabazitaxel and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cabazitaxel sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cabazitaxel market size, projected growth trends, production technologies, key applications, and end-use industries.
Cabazitaxel Segment by Company
Sanofi
Tapi Teva
Fuan Pharmaceutical Group
Fujian Yewpark Biological
Cabazitaxel Segment by Type
Purity above 99%
Other Purity
Cabazitaxel Segment by Application
Age Below 65
Age Above 65
Cabazitaxel Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cabazitaxel market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cabazitaxel and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cabazitaxel.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Cabazitaxel market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cabazitaxel manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cabazitaxel in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Cabazitaxel in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Purity above 99%
- Other Purity
Applications
- Age Below 65
- Age Above 65
Companies covered
- Sanofi
- Tapi Teva
- Fuan Pharmaceutical Group
- Fujian Yewpark Biological
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cabazitaxel Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cabazitaxel Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Cabazitaxel Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Cabazitaxel Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Cabazitaxel Market Dynamics
- 2.1 Cabazitaxel Industry Trends
- 2.2 Cabazitaxel Industry Drivers
- 2.3 Cabazitaxel Industry Opportunities and Challenges
- 2.4 Cabazitaxel Industry Restraints
3 Cabazitaxel Market by Manufacturers
- 3.1 Global Cabazitaxel Revenue by Manufacturers (2021-2026)
- 3.2 Global Cabazitaxel Sales by Manufacturers (2021-2026)
- 3.3 Global Cabazitaxel Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Cabazitaxel Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Cabazitaxel Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Cabazitaxel Manufacturers, Product Type & Application
- 3.7 Global Cabazitaxel Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Cabazitaxel Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Cabazitaxel Players Market Share by Revenue in 2025
- 3.8.3 2025 Cabazitaxel Tier 1, Tier 2, and Tier 3
4 Cabazitaxel Market by Type
- 4.1 Cabazitaxel Type Introduction
- 4.1.1 Purity above 99%
- 4.1.2 Other Purity
- 4.2 Global Cabazitaxel Sales by Type
- 4.2.1 Global Cabazitaxel Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cabazitaxel Sales by Type (2021-2032)
- 4.2.3 Global Cabazitaxel Sales Market Share by Type (2021-2032)
- 4.3 Global Cabazitaxel Revenue by Type
- 4.3.1 Global Cabazitaxel Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Cabazitaxel Revenue by Type (2021-2032)
- 4.3.3 Global Cabazitaxel Revenue Market Share by Type (2021-2032)
5 Cabazitaxel Market by Application
- 5.1 Cabazitaxel Application Introduction
- 5.1.1 Age Below 65
- 5.1.2 Age Above 65
- 5.2 Global Cabazitaxel Sales by Application
- 5.2.1 Global Cabazitaxel Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cabazitaxel Sales by Application (2021-2032)
- 5.2.3 Global Cabazitaxel Sales Market Share by Application (2021-2032)
- 5.3 Global Cabazitaxel Revenue by Application
- 5.3.1 Global Cabazitaxel Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Cabazitaxel Revenue by Application (2021-2032)
- 5.3.3 Global Cabazitaxel Revenue Market Share by Application (2021-2032)
6 Global Cabazitaxel Sales by Region
- 6.1 Global Cabazitaxel Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cabazitaxel Sales by Region (2021-2032)
- 6.2.1 Global Cabazitaxel Sales by Region (2021-2026)
- 6.2.2 Global Cabazitaxel Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cabazitaxel Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Cabazitaxel Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Cabazitaxel Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Cabazitaxel Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Cabazitaxel Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Cabazitaxel Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Cabazitaxel Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Cabazitaxel Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Cabazitaxel Revenue by Region
- 7.1 Global Cabazitaxel Revenue by Region
- 7.1.1 Global Cabazitaxel Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Cabazitaxel Revenue by Region (2021-2026)
- 7.1.3 Global Cabazitaxel Revenue by Region (2027-2032)
- 7.1.4 Global Cabazitaxel Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Cabazitaxel Revenue (2021-2032)
- 7.2.2 North America Cabazitaxel Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Cabazitaxel Revenue (2021-2032)
- 7.3.2 Europe Cabazitaxel Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Cabazitaxel Revenue (2021-2032)
- 7.4.2 Asia-Pacific Cabazitaxel Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Cabazitaxel Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Cabazitaxel Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Cabazitaxel Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi Cabazitaxel Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Tapi Teva
- 8.2.1 Tapi Teva Company Information
- 8.2.2 Tapi Teva Business Overview
- 8.2.3 Tapi Teva Cabazitaxel Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Tapi Teva Cabazitaxel Product Portfolio
- 8.2.5 Tapi Teva Recent Developments
- 8.3 Fuan Pharmaceutical Group
- 8.3.1 Fuan Pharmaceutical Group Company Information
- 8.3.2 Fuan Pharmaceutical Group Business Overview
- 8.3.3 Fuan Pharmaceutical Group Cabazitaxel Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Fuan Pharmaceutical Group Cabazitaxel Product Portfolio
- 8.3.5 Fuan Pharmaceutical Group Recent Developments
- 8.4 Fujian Yewpark Biological
- 8.4.1 Fujian Yewpark Biological Company Information
- 8.4.2 Fujian Yewpark Biological Business Overview
- 8.4.3 Fujian Yewpark Biological Cabazitaxel Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Fujian Yewpark Biological Cabazitaxel Product Portfolio
- 8.4.5 Fujian Yewpark Biological Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Cabazitaxel Value Chain Analysis
- 9.1.1 Cabazitaxel Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Cabazitaxel Production Mode & Process
- 9.2 Cabazitaxel Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Cabazitaxel Distributors
- 9.2.3 Cabazitaxel Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst